Conavi Medical Presents Data Demonstrating Feasibility of Saline-Based Hybrid IVUS–OCT Imaging with OCTIV™ at TCT 2026

Conavi Medical presented an animal-model study at TCT 2026 showing the feasibility of using saline instead of iodinated contrast during image acquisition with its OCTIV hybrid IVUS–OCT system; the study preceded use in patients. The FDA-cleared system is in commercial clinical use, with its first U.S. placement completed and patient cases ongoing.

Analysis

The investable signal is not the animal-model result itself; it is whether saline-based acquisition can preserve image quality in patients and become a repeatable workflow advantage. If validated, less reliance on iodinated contrast could make OCTIV more usable for patients where contrast exposure is a concern and strengthen its pitch to cath labs. But the mechanism is not automatically unique: IVUS-guided low- or zero-contrast procedures are an established alternative, so OCTIV must show that the hybrid image adds enough clinical value to justify workflow changes and equipment adoption.

Near term, the first U.S. placement and ongoing cases matter more than conference visibility. A single placement does not establish utilization, reorder economics, or broad demand. Over 1–3 months, look for patient-level evidence, additional placements, and signs that operators can use saline without compromising image quality or procedural efficiency. Over 6–18 months, successful validation could support differentiation against established intracoronary imaging options, but adoption and reimbursement remain separate hurdles.

The contrarian read is that the headline may overstate commercial significance: this is pre-patient feasibility, not evidence of improved outcomes or a cleared clinical protocol for contrast-free use. For CNVI, limited proof of commercial traction makes event-driven volatility and liquidity risk more relevant than near-term earnings sensitivity. The thesis weakens if human cases fail to reproduce image quality, saline use is not adopted in routine workflows, or placements do not broaden.

Key Decisions for Investors

• No directional trade on the animal-model finding alone. Treat CNVI as a high-volatility, evidence-gated watch rather than extrapolating clinical feasibility into near-term revenue.
• Set a catalyst alert for human data: verify sample size, image-quality endpoints, procedural success, and whether saline acquisition was used prospectively in patients. Do not assume the current FDA clearance covers this specific protocol.
• Track commercial proof over the next 1–3 months: additional U.S. placements, repeat use, and operator adoption. A placement count without utilization or repeat procedures is a weak demand signal.
• Revisit a speculative long only if patient-level results and expanding placements corroborate the workflow advantage; falsify the thesis on poor image quality, limited operator uptake, or no follow-on commercial evidence.